Form 4: Regeneron Director Bonnie L. Bassler Executes Stock Option and Sells Shares Under 10b5-1 Plan

Bonnie L. Bassler, a director at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on June 24, 2024, under a pre-arranged trading plan.

Summary

• On June 24, 2024, Bonnie L. Bassler, a director of Regeneron Pharmaceuticals, executed a transaction involving the company's stock.
• Bassler exercised non-qualified stock options to acquire 756 shares of common stock at an exercise price of $371.40.
• Simultaneously, Bassler sold 756 shares of Regeneron common stock at a price of $1,062.
• These transactions were conducted under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 27, 2024.
• Following these transactions, Bassler directly owns 1,382 shares of Regeneron common stock and 3,028 derivative securities (non-qualified stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine transactions under a pre-arranged trading plan and doesn't convey any specific positive or negative information about the company's performance or prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. Directors often use pre-arranged trading plans (Rule 10b5-1) to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates